Studies focused on treatment of Chronic Lymphocytic Leukemia (CLL)

Two clinical trial studies authored by groups of physicians that included physicians affiliated with US Oncology Research have been selected as "Best of ASH" which highlights the best studies from those presented and displayed in at American Society of Hematology's (ASH) Annual Meeting and Exposition. The "Best of ASH" will be presented at six locations in North America including Austin and Orlando Jan. 20-21, Atlanta and Las Vegas January 27-28, and New York City and San Francisco Feb. 3-4, as well as in Singapore March 3-4 and Foz do Iguacu, Brazil May 18-19. The two studies chosen are:
  • The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study - authored by Susan O'Brien, MD, Jan A. Burger, MD, PhD, Kristie A. Blum, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Jeff Sharman, MD , Ian W. Flinn, MD, PhD, Barbara Grant, MD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Tasheda Navarro, Eric Holmgren, PhD, Eric Hedrick, MD and John C. Byrd, MD; and
  • A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) - authored by Jeff Sharman, MD , Sven de Vos, MD, PhD, John P. Leonard, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, MD, PhD, Marshall T. Schreeder, Jaqueline C. Barrientos, MD, Nina D. Wagner-Johnston, Thomas Boyd, MD , Nathan H. Fowler, MD, Leanne Holes, Brian Lannutti, David Johnson, Thomas M. Jahn, and Langdon L. Miller.

"This is very exciting because both studies represent significant advancement in treatment of CLL," said - Riverbend. Sharman participated on both studies, and served as first author in the PI3K inhibitor CAL101 study.

He added, "The BTK study shows that PCI-32765 is an extremely well tolerated once daily pill with significant activity in CLL and Mantle Cell lymphoma. The response of this drug was very impressive and we are hopeful that the FDA will approve it rapidly after the appropriate studies are conducted. The study with CAL-101 shows that this family of drugs can be combined with many of the drugs we already use for CLL and that combinations are highly active against the disease." Kathryn Kolibaba, M.D., medical oncologist with , also made considerable contributions to the BTK study presented at ASH in December.

Thomas E. Boyd, MD, Medical Oncology/Hematology at in Yakima, Wash. agreed. "The PCI-32765 agent proved to be well tolerated over even a prolonged treatment course (> one year). This is very significant."

Roy Beveridge, M.D., chief medical officer, McKesson Specialty Health lauded Drs. Sharman and Boyd for their untiring efforts. "Our affiliated investigators are very committed to finding better ways to treat cancer and other types of blood diseases. The results of these studies are truly an indication of their hard work and determination."

Investigators affiliated with US Oncology Research and McKesson Specialty Health contributed to fifteen studies presented at the 2011 ASH Meeting AND published in print and online in the Nov. 18 supplemental volume of Blood . Clinical studies led by US Oncology Research affiliated physicians were also prominently featured at numerous other conferences held around the world, including the annual congress for the European Society for Medical Oncology ( ), the annual meeting for the American Society for Clinical Oncology ( ). Those studies, along with more than 72 published investigator-initiated manuscripts, featured forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow. For a complete list, please contact US Oncology Research at 281-863-1000.

About US Oncology Research

, which draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in over 250 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 50,000 patients in over 1,200 trials since inception in 1992 and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit .

About McKesson Specialty Health

, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our customers and help them provide quality care for patients. For more information, visit .

PR Contact

US Oncology Research
Chris Perez, 281-863-5686
Chris.Perez@USOncology.com
or
McKesson Specialty Health
Joanna Katz, 650-871-3363
Joanna.Katz@McKesson.com



distribué par

Ce noodl a été diffusé par McKesson Corporation et initialement mise en ligne sur le site http://www.mckesson.com. La version originale est disponible ici.

Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-20 18:53:22 PM et restera accessible depuis ce lien permanent.

Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité.